Jiangsu Hengrui Medicine Co., Ltd.
Clinical trials sponsored by Jiangsu Hengrui Medicine Co., Ltd., explained in plain language.
A pharmaceutical company developing drugs in oncology, anesthesia, and more.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new daily pill slow advanced prostate cancer? Results expected Sep 2026 (estimated)
- Healthy volunteers to test new formulation of breast cancer drug HRS-6209 Results expected Sep 2026 (estimated)
- New pain jab could cut opioid use in kids after surgery Results expected Sep 2026 (estimated)
- New painkiller could ease recovery after lung surgery Results expected Nov 2026 (estimated)
- New hope for Hard-to-Treat lung cancer: targeted drug combo enters human trials Results expected Dec 2026 (estimated)
-
Can a new drug combo outsmart RAS-Mutated pancreatic cancer?
Disease control Not yet recruitingThis trial tests whether an experimental drug called HRS-7172, when combined with other antitumor therapies, can safely shrink or control advanced pancreatic cancer that has RAS mutations or amplifications. The study includes adults aged 18 to 70 with locally advanced or metastat…
Phase 1/2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a targeted drug combo shrink Hard-to-Treat colorectal tumors?
Disease control Not yet recruitingThis trial tests whether adding trastuzumab rezetecan, a targeted antibody-drug, to standard chemotherapy and bevacizumab can safely control advanced colorectal cancer that carries the HER2 marker. Researchers will enroll 48 people with HER2-positive, unresectable or metastatic c…
Phase 2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a new drug outperform chemotherapy for tough esophageal cancer?
Disease control Not yet recruitingThis phase III trial compares an experimental drug called FH-006 with standard chemotherapy in people with advanced esophageal squamous cell carcinoma that has progressed after initial treatment. The study aims to see if FH-006 can help patients live longer. Participants will be …
Phase 3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a new pill tame ulcerative colitis?
Disease control Not yet recruitingThis early-stage trial is testing an experimental oral medication called HRS-7085 in adults with moderate to severe ulcerative colitis, a chronic inflammatory bowel disease. The main goal is to see if the drug is safe and tolerable, and to understand how it moves through the body…
Phase 1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new drug improve muscle relaxation during surgery?
Disease control Not yet recruitingThis trial tests whether an experimental drug called HRS-9190 can safely and effectively relax muscles during general anesthesia for elective surgery. It compares HRS-9190 to a standard muscle relaxant, rocuronium, in about 320 adults. The study measures how well the drug enables…
Phase 3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC